IGC Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

IGC Pharma wird ein Gewinn- und Umsatzwachstum von 2.9% bzw. 13.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 23.1% pro Jahr wachsen soll.

Wichtige Informationen

3.3%

Wachstumsrate der Gewinne

24.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	12.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	01 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

Feb 27

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:IGC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	2	-13	N/A	-5	1
3/31/2026	1	-11	N/A	-6	2
3/31/2025	1	-10	N/A	-8	1
6/30/2024	1	-13	-6	-5	N/A
3/31/2024	1	-13	-6	-5	N/A
12/31/2023	1	-14	-7	-6	N/A
9/30/2023	1	-11	-7	-6	N/A
6/30/2023	1	-11	-7	-6	N/A
3/31/2023	1	-12	-8	-7	N/A
12/31/2022	1	-14	-7	-6	N/A
9/30/2022	1	-14	-8	-7	N/A
6/30/2022	1	-16	-9	-8	N/A
3/31/2022	0	-15	-8	-7	N/A
12/31/2021	0	-11	-9	-9	N/A
9/30/2021	0	-11	-9	-9	N/A
6/30/2021	0	-9	-9	-9	N/A
3/31/2021	1	-9	-12	-11	N/A
12/31/2020	1	-9	-12	-10	N/A
9/30/2020	1	-8	-14	-11	N/A
6/30/2020	3	-8	-14	-10	N/A
3/31/2020	4	-7	-13	-9	N/A
12/31/2019	6	-6	-12	-8	N/A
9/30/2019	6	-5	-9	-7	N/A
6/30/2019	5	-5	-7	-6	N/A
3/31/2019	5	-4	-3	-3	N/A
12/31/2018	5	-3	-3	-3	N/A
9/30/2018	4	-2	-2	-2	N/A
6/30/2018	4	-2	-2	-2	N/A
3/31/2018	2	-2	N/A	-2	N/A
12/31/2017	1	-2	N/A	-2	N/A
9/30/2017	1	-2	N/A	-1	N/A
6/30/2017	0	-2	N/A	-2	N/A
3/31/2017	1	-2	N/A	-1	N/A
12/31/2016	2	-3	N/A	-1	N/A
9/30/2016	3	-3	N/A	-1	N/A
6/30/2016	5	-3	N/A	1	N/A
3/31/2016	6	-3	N/A	0	N/A
12/31/2015	7	-3	N/A	0	N/A
9/30/2015	9	-4	N/A	-1	N/A
6/30/2015	9	-4	N/A	-3	N/A
3/31/2015	8	-5	N/A	-3	N/A
12/31/2014	5	-4	N/A	-3	N/A
9/30/2014	3	-4	N/A	-3	N/A
6/30/2014	2	-4	N/A	-2	N/A
3/31/2014	2	-3	N/A	-2	N/A
12/31/2013	4	-3	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IGC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IGCDie Einnahmen des Unternehmens (13.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.5% pro Jahr).

Hohe Wachstumseinnahmen: IGCDie Einnahmen des Unternehmens (4.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IGC in 3 Jahren voraussichtlich hoch sein wird

IGC Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 21%

Consensus revenue estimates increase by 12%

Recent updates

Independent Director recently bought US$200k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

Consensus revenue estimates decrease by 21%

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma, Inc. Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

Independent Chairman of the Board notifies of intention to sell stock

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates increase by 12%

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

IGC Pharma's Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease

IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer’S At Week Two Compared to Placebo

New minor risk - Share price stability

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $6.24051 million.

President notifies of intention to sell stock

Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.309602 million.

Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer’S Trial

New major risk - Financial position

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.047 loss in 2Q 2023)

IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico

IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited and other investors

IGC Pharma, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.042 loss per share (vs US$0.047 loss in 3Q 2022)

India Globalization Capital, Inc. Receives No Objection Letter from Health Canada

India Globalization Capital, Inc. Announces Board Changes

India Globalization Capital, Inc. Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Second quarter 2023 earnings released: US$0.047 loss per share (vs US$0.087 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.054 loss per share (vs US$0.037 loss in 1Q 2022)

India Globalization Capital, Inc., Annual General Meeting, Sep 09, 2022

Full year 2022 earnings released: US$0.30 loss per share (vs US$0.21 loss in FY 2021)

India Globalization Capital, Inc. Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

India Globalization Capital, Inc. Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

India Globalization Capital, Inc. Announces Positive Primary Endpoint Data for Its Phase 1 Clinical Trial for IGC-AD1

India Globalization Capital, Inc. Announces Preliminary Results for its Exploratory Endpoints from its Phase 1 IGC-AD1 Clinical Trial

India Globalization Capital, Inc. to Present Preliminary Positive Secondary End Point Findings from its Phase 1 Clinical Trial for IGC-AD1

Second quarter 2022 earnings released: US$0.087 loss per share (vs US$0.04 loss in 2Q 2021)

Independent Chairman of the Board notifies of intention to sell stock

India Globalization Capital, Inc. Completes Its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

First quarter 2022 earnings released: US$0.037 loss per share (vs US$0.047 loss in 1Q 2021)

India Globalization Capital, Inc Announces Issuance of Patent for the Treatment of Alzheimer’S Disease Using THC

India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. Completes Cohort 1 of Its Phase 1 Thc-Based Clinical Trial on Alzheimer’S Patients

Independent Chairman of the Board recently sold US$90k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Does India Globalization Capital's (NYSEMKT:IGC) CEO Salary Compare Well With Industry Peers?

India Globalization Capital, Inc. Provides Update on Phase 1 Clinical Trial on Alzheimer’S Patients

Third quarter 2021 earnings released: US$0.056 loss per share (vs US$0.041 loss in 3Q 2020)

India Globalization Capital, Inc. Approves the Election of John E. Lynch to the Board of Directors

India Globalization Capital, Inc., Annual General Meeting, Jan 11, 2021

India Globalization Capital, Inc. Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’S Patients

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc.(AMEX:IGC) dropped from Russell Microcap Index

India Globalization Capital, Inc. announced delayed annual 10-K filing

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken